Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Januvia (sitagliptin by Year
Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide sales ($M) ($M)
Merck Januvia (sitagliptin: $1,604M in FY2025, up 20.2% from a year earlier.
Where the FY2025 figure comes from
“|| Januvia | 367 | 258 | 625 | 549 | 372 | 921 | 382 | 302 | 1,604 | -31 | -30 | -32 | -32”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,604 | +20.2% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 1,334 | -39.1% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 2,189 | -22.2% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 2,813 | -15.4% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 3,324 | +0.5% | Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗ |
| FY2020 | Dec 31, 2020 | 3,306 | -5.1% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 3,482 | -5.5% | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 3,686 | -1.4% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 3,737 | -4.4% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 3,908 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up januvia (sitagliptin
- Januvia (sitagliptin — DPP-4 inhibitor) — U.S. sales ($M)999 · FY2025
- Januvia (sitagliptin — DPP-4 inhibitor) — International sales ($M)605 · FY2025
- Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide reported growth YoY (%)20.0% · FY2025
- Januvia (sitagliptin — DPP-4 inhibitor) — Worldwide constant-currency (ex-exchange) growth YoY (%)21.0% · FY2025
Cite this data
StockData. (2026). Merck Januvia (sitagliptin ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-januvia
See every metric in the Merck KPI table. Data updated Oct 26, 2026.